Tongshu Gene Closes Series B of Multi-Hundreds Millions
Tongshu Gene announced the close of Series B of multi-hundreds of millions on September 22, 2020. YuanBio Venture Capital led the investment, participated by Lang Ma Feng Ventures, XiRan Capital and Jiangsu Tuobang Investment. The bankroll will help accelerate the clinical development and product pipeline of the In-vitro diagnosis (IVD) technology.
Founded in 2016, Tongshu Gene is a biotechnology company that focuses on the genetic detection for oncology. In January 2020, DeepBlue Technology, a tier-one AI platform company, wholly acquired the Fangcheng Medical Examination Company from Tongshu Gene.